• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Mackenzie's Mission HomepageMackenzie's Mission

DONATE Mackenzies Mission Donate
  • Mission
  • About
    • The Story
    • Board
  • Resources
    • Resource List
    • What Is Amyloidosis
  • Speakers Bureau
    • About ASB
    • ASB Operating Committee
  • Fundraisers
  • Blog
  • Contact

amyloidosis treatment

Inflation Reduction Act of 2022 & Amyloidosis

August 31, 2023

Despite the well-intended goal of lowering prescription drug costs generally and allowing drug prices for Medicare recipients to be negotiated, there remains much to unravel about the effects of the new Inflation Reduction Act. It will likely save many people money but there is concern, especially regarding the medications for the treatment of rare diseases such as amyloidosis, and about what appears to be a disincentive to pharmaceutical companies to engage in costly research and development to treat these rare diseases. The challenge to diagnosis and providing effective, affordable treatment to amyloidosis patients continues.

Filed Under: Featured News Tagged With: amyloidosis, amyloidosis news, amyloidosis treatment

Multidisciplinary Care for Cardiac Amyloidosis Patients

June 24, 2023

Multi-systemic diseases such as amyloidosis are not only complex to diagnose, but also complex in the treatment and ongoing patient care. It takes a village. In this seminal piece, the American College of Cardiology (ACC) provides an Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis. An absolute must-read for cardiologists and other specialties such as neurology, gastroenterology, nephrology and hematology.

Filed Under: Featured News, What Is Amyloidosis Tagged With: AL amyloidosis, Amyloid cardiomyopathy, amyloidosis, amyloidosis treatment, ATTR amyloidosis, ATTR-CM, attrv, ATTRwt, cardiac amyloidosis, cardiology, gastroenterology, hATTR, heart failure, hematology, Hereditary Amyloidosis, light chain amyloidosis, nephrology, neurology, wild-type amyloidosis

CRISPR/Cas9 – ATTR Clinical Trial Update

November 17, 2022

Per the National Institute of Health, “One of the most promising areas of research in recent years has been gene editing, including CRISPR/Cas9, for fixing misspellings in genes to treat or even cure many conditions.” In this piece we provide a clinical trial update for transthyretin (TTR) amyloidosis using this technology.

Filed Under: Featured News, What Is Amyloidosis Tagged With: #crispr, Amyloid cardiomyopathy, amyloidosis, amyloidosis diagnosis, amyloidosis research, amyloidosis treatment, ATTR amyloidosis, ATTRwt, hATTR

FDA Approved AMVUTTRA for hATTR

June 14, 2022

Alnylam Announces FDA Approval of AMVUTTRA™ (vutrisiran), an RNAi Therapeutic for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults

Filed Under: Featured News, What Is Amyloidosis Tagged With: amyloidosis, amyloidosis treatment, ATTR amyloidosis, attrv, FDA Approved, hATTR, Hereditary Amyloidosis

AL Amyloidosis vs Multiple Myeloma

October 28, 2021

In reality, while there are ample similarities where some view AL amyloidosis and multiple myeloma as “cousins,” there are important differences.

Filed Under: Featured News, What Is Amyloidosis Tagged With: AL amyloidosis, amyloidosis, amyloidosis treatment, blood diseases, light chain amyloidosis, multiple myeloma

  • Go to page 1
  • Go to page 2
  • Go to page 3
  • Interim pages omitted …
  • Go to page 6
  • Go to Next Page »

Primary Sidebar

Recent News

  • Inflation Reduction Act of 2022 & Amyloidosis
  • A Patient Guide for Understanding Amyloidosis
  • Multidisciplinary Care for Cardiac Amyloidosis Patients
  • ATTR-CM: Don’t Assume it’s Wild-Type TTR Amyloidosis
  • Helping Patients Find Their Voice

Be A Part Of Our Mission!

Join our mailing list to receive the latest news and updates from our team.

You have Successfully Subscribed!

  • Mission
  • About
  • Resources
  • Speakers Bureau
  • Fundraisers
  • Blog
  • Contact

Registered 501(c)(3) · Contact · Copyright © 2023 · Mackenzies Mission - All Rights Reserved